{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T12:16:03Z","timestamp":1783426563002,"version":"3.54.6"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":152,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine Case Reports"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.rmcr.2026.102444","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:14:02Z","timestamp":1780445642000},"page":"102444","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Successful Re-challenge of zongertinib following erythema multiforme-like drug eruption in a patient with HER2-mutant non-small cell lung cancer"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6981-0648","authenticated-orcid":false,"given":"Kodai","family":"Kawamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Ichikado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmcr.2026.102444_bib1","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1200\/JCO-24-01727","article-title":"HER2-selective tyrosine kinase inhibitor, zongertinib (BI 1810631), in patients with advanced\/metastatic solid tumors with HER2 alterations: a phase Ia dose-escalation study","volume":"43","author":"Heymach","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.rmcr.2026.102444_bib2","first-page":"e531","article-title":"Prevention and management of dermatological toxicities related to HER2-targeted therapies","volume":"22","author":"Lacouture","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.rmcr.2026.102444_bib3","first-page":"332","article-title":"Erythema multiforme induced by pyrotinib in a patient with HER2-positive metastatic breast cancer: a case report","volume":"34","author":"Ying","year":"2022","journal-title":"J. Chemother."},{"key":"10.1016\/j.rmcr.2026.102444_bib4","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/annonc\/mdz077","article-title":"Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib","volume":"30","author":"Schoenfeld","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.rmcr.2026.102444_bib5","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1001\/jamaoncol.2017.4526","article-title":"EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer","volume":"4","author":"Oshima","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.rmcr.2026.102444_bib6","first-page":"285","article-title":"EGFR-system-mediated self-renewal of mammary epithelial stem cells","volume":"201","author":"Nanba","year":"2013","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.rmcr.2026.102444_bib7","first-page":"1866","article-title":"Successful desensitization to gefitinib in a patient with EGFR-mutated non-small-cell lung cancer","volume":"5","author":"Bareschino","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.rmcr.2026.102444_bib8","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1177\/1078155220918644","article-title":"Successful alectinib desensitization in a patient with anaplastic lymphoma kinase-positive adenocarcinoma of the lung and alectinib-induced drug rash","volume":"26","author":"Anderson","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.rmcr.2026.102444_bib9","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1097\/CAD.0000000000000669","article-title":"Imatinib-induced drug reaction with eosinophilia and systemic symptoms in solid tumors: a patient with dermatofibrosarcoma protuberans and successful desensitization management","volume":"29","author":"Ben-Ami","year":"2018","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.rmcr.2026.102444_bib10","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3390\/medicina58040511","article-title":"Successful dabrafenib desensitization protocols in a patient with metastatic melanoma","volume":"58","author":"Bumbacea","year":"2022","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.rmcr.2026.102444_bib11","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.3390\/curroncol30030218","article-title":"Canada's first joint oncology-allergy clinic: successful desensitization to trastuzumab following severe anaphylactic reaction","volume":"30","author":"Robinson","year":"2023","journal-title":"Curr. Oncol."}],"container-title":["Respiratory Medicine Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221300712600081X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221300712600081X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T11:33:05Z","timestamp":1783423985000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221300712600081X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":11,"alternative-id":["S221300712600081X"],"URL":"https:\/\/doi.org\/10.1016\/j.rmcr.2026.102444","relation":{},"ISSN":["2213-0071"],"issn-type":[{"value":"2213-0071","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Successful Re-challenge of zongertinib following erythema multiforme-like drug eruption in a patient with HER2-mutant non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmcr.2026.102444","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102444"}}